Natixis acquired a new stake in Spark Therapeutics Inc (NASDAQ:ONCE) during the second quarter, according to its most recent filing with the SEC. The firm acquired 103,665 shares of the biotechnology company’s stock, valued at approximately $10,613,000. Natixis owned about 0.27% of Spark Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ONCE. CNH Partners LLC acquired a new stake in shares of Spark Therapeutics during the 1st quarter worth approximately $89,851,000. Alpine Associates Management Inc. boosted its stake in Spark Therapeutics by 13.3% in the second quarter. Alpine Associates Management Inc. now owns 784,100 shares of the biotechnology company’s stock valued at $80,277,000 after acquiring an additional 91,800 shares during the last quarter. IndexIQ Advisors LLC bought a new position in Spark Therapeutics in the first quarter valued at approximately $76,059,000. Gabelli Funds LLC boosted its stake in Spark Therapeutics by 5.1% in the second quarter. Gabelli Funds LLC now owns 622,467 shares of the biotechnology company’s stock valued at $63,728,000 after acquiring an additional 30,329 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Spark Therapeutics by 1.0% during the 2nd quarter. Northern Trust Corp now owns 408,962 shares of the biotechnology company’s stock worth $41,868,000 after acquiring an additional 4,004 shares during the period. Hedge funds and other institutional investors own 86.34% of the company’s stock.

ONCE traded up $0.11 during mid-day trading on Wednesday, hitting $101.85. The stock had a trading volume of 141,076 shares, compared to its average volume of 359,052. The stock’s fifty day simple moving average is $99.73 and its 200-day simple moving average is $105.08. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.56 and a quick ratio of 5.22. The firm has a market capitalization of $3.87 billion, a price-to-earnings ratio of -48.27 and a beta of 2.07. Spark Therapeutics Inc has a 1-year low of $34.53 and a 1-year high of $114.20.

ONCE has been the subject of several recent research reports. Mizuho reiterated a “hold” rating and set a $114.50 target price on shares of Spark Therapeutics in a research report on Monday, August 12th. Zacks Investment Research downgraded Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $87.92.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Recommended Story: Growth Stocks

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.